Best practices for agentic clinical trial and R&D data: a field guide for clinical and R&D data teams
How clinical and R&D data teams move their data back office to agents, practice by practice: the state of the space, the old world and the new, what the agents do step by step, how to set autonomy, who owns what, and how to start.
Pharma's past trials are its most underused asset.
Pooling them is repeatable work: profile, map, anonymize, document. Agents should run it as each study closes.
The state of the space
Teams that own trial data (SDTM, ADaM), preclinical and discovery data and the platforms that pool them for reuse. They sit in enterprise R&D data platforms, clinical data management or a data science and AI organization. Titles include Head of Data Engineering & Data Products, Clinical Data SME, Data Product Owner (R&D) and Head of Data Governance, Anonymization & Quality.
Pharma companies have run thousands of trials, and most of that data sits in study-specific silos. Pooling it for AI and secondary research needs standardization, anonymization and governance at a scale no team can staff by hand. Agents make pooling continuous: every new study is profiled, standardized, anonymized and documented as it closes.
The old world
A study locks and waits six weeks for mapping and privacy review before scientists can use it.
It is rarely one failure. Three patterns repeat:
- •Pooling 2,000 studies. Each study is mapped by hand to a common model.
- •Anonymization as code. Every secondary-use request needs a privacy review.
- •A scientist's pooled question. A data scientist needs adverse events across 40 studies.
The new world
The study was profiled, mapped, anonymized and pooled within a day; two exceptions went to the governance lead.
Here is that new world as a chain of hand-offs between agents:
These are the impact metrics we move:
- •Access decision: from about a week to ~1 h
- •Metadata for a study: from about 3 days to under 1 h
- •Anonymization review: from about a week to hours
The rest of this report walks through the 5 practices that make that possible. At a glance:
The practices, one by one
1. Pool at database lock
Waiting multiplies the backlog.
Why it is harder than it looks. Pooling later means pooling never; backlogs compound.
The old world. Quarterly pooling.
The new world. Onboarding runs on lock.
What the agents do, step by step:
- 1.The Data Ingestion agent calls
get_connector_statusand picks up locked studies. - 2.The Pipeline Building agent calls
generate_pipelineand adds the study to the pool. - 3.The Quality Monitoring agent calls
create_quality_tests_for_pipelineand adds checks.
In practice. A study is reusable the week it closes.
What to measure. Days from lock to pool.
2. Anonymize as code
Consistency is the control.
Why it is harder than it looks. Every reviewer anonymizes slightly differently.
The old world. Study-by-study review.
The new world. Data Security applies rules; exceptions to a person.
What the agents do, step by step:
- 1.The Data Security agent calls
scan_piiand classifies identifiers. - 2.The Data Security agent calls
review_pii_writesand checks outputs. - 3.The Data Access & Governance agent calls
request_governance_reviewand routes exceptions.
In practice. Two exceptions instead of a full review.
What to measure. Studies reviewed by hand.
Practices like these compound. Across the routine work they cover:
3. Map deviations, don't rebuild
Most studies are almost standard.
Why it is harder than it looks. Most studies deviate from the standard in a few domains, not everywhere.
The old world. Full remapping.
The new world. Schema Evolution maps deviations.
What the agents do, step by step:
- 1.The Schema Evolution agent calls
detect_schema_changeand finds deviations. - 2.The Schema Evolution agent calls
generate_migrationand maps them. - 3.The Pipeline Building agent calls
sandbox_testand tests them.
In practice. Four deviations mapped in an hour.
What to measure. Hours per study.
4. Document consent and lineage
Reuse depends on it.
Why it is harder than it looks. Reuse fails audit without consent and provenance.
The old world. Incomplete metadata.
The new world. Context & Catalog documents both.
What the agents do, step by step:
- 1.The Data Context & Catalog agent calls
generate_documentationand documents provenance. - 2.The Data Context & Catalog agent calls
trace_cross_platform_lineageand links records to sources. - 3.The Data Access & Governance agent calls
check_policyand checks consent basis.
In practice. Every pooled record traceable.
What to measure. Datasets with consent on record.
Autonomy where work is reversible, a named approver where it matters:
5. Grant access by purpose
Science shouldn't wait on tickets.
Why it is harder than it looks. Scientists need answers in the week the question matters.
The old world. Per-study approvals.
The new world. Policy-based access.
What the agents do, step by step:
- 1.The Data Access & Governance agent calls
check_policyand checks purpose. - 2.The Data Access & Governance agent calls
provision_accessand grants access. - 3.The Data Access & Governance agent calls
generate_audit_reportand logs it.
In practice. A scientist gets data in a day.
What to measure. Days to access.
Designing the autonomy ladder
Autonomy is set per task class, not per tool. This is where we would set each class for a mature deployment, and why:
| Task class | Closed autonomously | Escalated | Handled by a person | Where we set it | Why |
|---|---|---|---|---|---|
| Metadata upkeep | 88% | 8% | 4% | L4 once the receipts are clean | The work is reversible and repeatable |
| Study mapping | 60% | 30% | 10% | L3: acts and keeps a rollback point | Most cases are routine; the rest escalate with evidence |
| Pooling reruns | 78% | 16% | 6% | L3: acts and keeps a rollback point | Most cases are routine; the rest escalate with evidence |
| Anonymization | 40% | 46% | 14% | L3 for routine cases, L2 for the rest | Judgment is needed often enough to keep a person close |
| Identified-data access | 0% | 86% | 14% | L2: always proposed to a named approver | The number carries accountability outside the data team |
The operating model: who owns what
Agents change who does the work, not who is accountable for it:
| Role | Owns | What the agents take off their plate |
|---|---|---|
| Head of Clinical Data Products | Standards, autonomy levels per domain and which domain goes next | Assembling status, chasing owners, keeping the catalog current |
| Domain owners and approvers | Anonymization exceptions and identified-data access | Preparing the diff, blast radius and rollback plan for every proposal |
| Data engineers | Reviewing agent proposals and building new data products | Studies are profiled, mapped and pooled at database lock; anonymization rules apply consistently |
The swarm behind the practices
| Agent | What it does for you | Tools it calls |
|---|---|---|
| Data Ingestion | Profiles closed studies and new data deliveries | get_connector_status, trigger_airflow_dag, register_kafka_schema |
| Schema Evolution | Maps study deviations to SDTM/ADaM | detect_schema_change, validate_schema_compatibility, generate_migration, rollback_migration |
| Data Security | Anonymization and sensitive-data classification | scan_pii, review_pii_writes, pci_card_data_masking |
| Pipeline Building | Pooling pipelines with tests | generate_pipeline, validate_pipeline, sandbox_test, deploy_pipeline |
| Data Context & Catalog | Metadata, lineage and governed definitions | trace_cross_platform_lineage, blast_radius_analysis, define_business_rule, generate_documentation |
| Data Access & Governance | Consent- and purpose-based access | provision_access, check_policy, request_governance_review, generate_audit_report |
Data Context Wizard keeps one governed graph of definitions, lineage and owners that every agent and person answers from. Autonomous Data-Conductor runs each job from detection to a verified result. Spellbook Data Catalog is where your team approves, audits and rolls back, and asks questions in plain English.
What disappears
- •Six-week study queues.
- •Study-by-study privacy reviews.
- •Incomplete metadata.
- •Per-study access tickets.
- •Rebuilt pooled datasets.
The magic is not any single agent. It is that the back office keeps running: bad data is caught where it enters, every new table gets quality rules and documentation without anyone writing them, access follows policy, fixes are verified before anyone opens a dashboard, and every action leaves a signed receipt.
A product manager's scorecard
| Metric | How to read it |
|---|---|
| Days from lock to pool | Baseline it in the first week of the pilot; review it monthly. |
| Studies needing manual review | Baseline it in the first week of the pilot; review it monthly. |
| Pooled datasets with consent on record | Baseline it in the first week of the pilot; review it monthly. |
| Days to access | Baseline it in the first week of the pilot; review it monthly. |
| Studies reused per quarter | Baseline it in the first week of the pilot; review it monthly. |
Where this goes next
R&D data platforms will pool every study at lock, anonymize by rule and let scientists ask questions across decades of trials in days. The pharma companies that get there will run AI on all of their evidence, not the latest study.
The climb: from assisted to autonomous to agentic
Our thesis is that the data platform climbs the way analytics did, in stages, and that the hard part of data work was never knowing what to do but doing it. For clinical and R&D data teams, the climb looks like this:
- •Assisted. Agents work alongside your team. They read the whole stack, show what needs doing and propose every fix with a receipt; anonymization exceptions and identified-data access always go to a named approver.
- •Autonomous, under your governance. Routine work runs on its own: studies are profiled, mapped and pooled at database lock, anonymization rules apply consistently, and consent basis and lineage are documented for every pooled record. Your team governs the agents instead of doing the upkeep.
- •The agentic enterprise. R&D data platforms will pool every study at lock, anonymize by rule and let scientists ask questions across decades of trials in days. The pharma companies that get there will run AI on all of their evidence, not the latest study.
You choose the altitude, every step is visible and reversible, and the pilot below is the first rung.
The pilot: how clinical and R&D data teams start
The pilot is how your team proves the value on its own data before committing.
- •What we connect. Databricks or Snowflake; EDC and CTMS exports; SAS and R programming environments; metadata repositories; dbt or Spark pipelines, over MCP, inside your infrastructure. Nothing migrates.
- •Scope. Pool 50 recent studies at L2 for anonymization exceptions.
- •First week. Agents run at L1 across the scoped domain. They map every pipeline, definition and lineage path and show the fixes they would have made, with receipts, so your team sees the value before anything changes.
- •By week two. Studies are profiled, mapped and pooled at database lock and anonymization rules apply consistently start running on reversible work. Anonymization exceptions and identified-data access stay at L2 with a named approver.
- •At day 30. We review the impact metrics against your baseline:
- •Access decision: from about a week to ~1 h
- •Metadata for a study: from about 3 days to under 1 h
- •Anonymization review: from about a week to hours
- •the share of metadata upkeep closed autonomously, targeting 88% as the deployment matures
- •What you decide. Whether to expand to the next domain. The pilot fee is credited in full against the first year.
- •Cost. Start with a pilot ($7,500 one-time, credited in full against the first year). Scale is from $1,000 a month and Enterprise from $3,000 a month, billed annually, with unlimited seats, no usage meter and no markup on model spend. See pricing.
The pilot is the start of a longer curve:
Read the full playbook: Data Workers for clinical and R&D data teams